Bio-Techne Corporation Stock

$54.63

0.55%

Nasdaq, Aug 29, 10:31 pm CET

ISIN

US09073M1045

Symbol

TECH

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Bio-Techne Corporation Stock price

$54.63

-9.24 14.46% 5Y

Nasdaq, Closing price Fri, Aug 29 2025

+0.30 0.55%

ISIN

US09073M1045

Symbol

TECH

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$8.5b

Enterprise Value

$8.7b

Net debt

$183.8m

Cash

$162.2m

Shares outstanding

155.0m

Valuation (TTM | estimate)

P/E

121.4 | 26.6

P/S

7.0 | 6.7

EV/Sales

7.1 | 6.8

EV/FCF

33.8

P/B

4.4

Dividends

DPS

$0.32

Yield 1Y | 5Y

0.6% | 0.4%

Growth 1Y | 5Y

0.0% | 0.0%

Payout 1Y | 3Y

69.6% | 29.4%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$1.2b | $1.3b

EBITDA

$333.6m | $464.0m

EBIT

$223.7m | $416.1m

Net Income

$72.3m | $317.9m

Free Cash Flow

$256.6m

Growth (TTM | estimate)

Revenue

-15.1% | 4.1%

EBITDA

-19.7% | 81.9%

EBIT

-26.4% | 86.0%

Net Income

-67.0% | 333.4%

Free Cash Flow

8.7%

Financial Health

Equity Ratio

75.0%

Return on Equity

3.8%

ROCE

9.4%

ROIC

7.1%

Debt/Equity

0.2

EPS

$0.5

FCF per Share

$1.7

Short interest

4.3%

Employees

Rev per Employee

$390.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

??

24 Analysts have issued a Bio-Techne Corporation forecast:

17x Buy

71%

7x Hold

29%

More details on Analyst Estimates Including Price Targets

24 Analysts have issued a Bio-Techne Corporation forecast:

Buy

71%

Hold

29%

Analyst Estimates with Stock Price Targets

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	1,220 1,220	15% 15% 100%
- Direct Costs	418 418	13% 13% 34%
Gross Profit	802 802	16% 16% 66%
- Selling and Administrative Expenses	479 479	10% 10% 39%
- Research and Development Expense	100 100	18% 18% 8%
EBITDA	334 334	20% 20% 27%
- Depreciation and Amortization	110 110	2% 2% 9%
EBIT (Operating Income) EBIT	224 224	26% 26% 18%
Net Profit	72 72	67% 67% 6%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bio-Techne Corporation Stock News

Neutral

PRNewsWire

●

5 days ago

Bio-Techne to Present at Upcoming Investor Conferences

MINNEAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference September 3, 2025 10:15 AM EDT Baird 2025 Global Healthcare Conference September 9, 2025 9:05 AM EDT Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT A live webc...

Neutral

PRNewsWire

●

18 days ago

ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory

ST. PAUL, Minn. , Aug. 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant ...

Neutral

The Motley Fool

●

26 days ago

Bio-Techne (TECH) Q4 EPS Rises 8.2%

More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office	United States
CEO	Kim Kelderman
Employees	3,100
Founded	1976
Website	www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now